anurajms/meta_analysis huggingface dataset:
Provide patient population that should be included in the study
Topical pharmacologic interventions versus placebo for epidemic keratoconjunctivitis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Epidemic Keratoconjunctivitis 4. Adult 19-44 years 5. Child 6-12 years 6. Middle Aged 45-64 years 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Pneumatic retinopexy versus scleral buckle for repairing simple rhegmatogenous retinal detachments
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Retinal Detachment 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Fornix‐based versus limbal‐based conjunctival trabeculectomy flaps for glaucoma
1. Aged 80 and over 80+ years 2. Glaucoma 3. Adult 19-44 years 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Intraocular lens optic edge design for the prevention of posterior capsule opacification after cataract surgery
1. Aged 80 and over 80+ years 2. Extraction Of Cataract 3. Middle Aged 45-64 years 4. Aged 65-79 years
Provide patient population that should be included in the study
Adjunctive modulation of wound healing during cataract surgery to promote survival of a previous trabeculectomy
1. Aged 80 and over 80+ years 2. Cataract 3. Normal tension glaucoma 4. Aged 65-79 years 5. Primary Open Angle Glaucoma 6. Adult 19-44 years 7. Middle Aged 45-64 years 8. Young Adult 19-24 years 9. Pigmentary Glaucoma 10. Angle-closure Glaucoma 11. Neovascular Glaucoma 12. Uveitic Glaucoma 13. Pseudoexfoliation Glaucoma 14. Glaucoma surgery
Provide patient population that should be included in the study
Photobiomodulation for non‐exudative age‐related macular degeneration
1. Aged 80 and over 80+ years 2. Middle Aged 45-64 years 3. Age-related Macular Degeneration 4. Aged 65-79 years
Provide patient population that should be included in the study
Surgery for idiopathic epiretinal membrane
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Aged 65-79 years 6. Epiretinal Membrane
Provide patient population that should be included in the study
Lens extraction for chronic angle‐closure glaucoma
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Angle-closure Glaucoma 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Laser peripheral iridoplasty for chronic angle closure
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Primary Angle-closure Glaucoma 6. Middle Aged 45-64 years 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Ab interno trabecular bypass surgery with Trabectome for open‐angle glaucoma
1. Aged 80 and over 80+ years 2. Child, Preschool 2-5 years 3. Child 6-12 years 4. Infant 1 to 23 mo 5. Aged 65-79 years 6. Adolescent 13-18 years 7. Adult 19-44 years 8. Middle Aged 45-64 years 9. Ocular Hypertension 10. Borderline open-angle Glaucoma 11. Young Adult 19-24 years 12. Pigmentary Glaucoma 13. Pseudoexfoliation Glaucoma 14. Open-angle Glaucoma
Provide patient population that should be included in the study
Wavefront excimer laser refractive surgery for adults with refractive errors
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Aged 65-79 years 6. Refractive Errors
Provide patient population that should be included in the study
Visual cycle modulators versus placebo or observation for the prevention and treatment of geographic atrophy due to age‐related macular degeneration
1. Age-related Macular Degeneration
Provide patient population that should be included in the study
Corneal collagen cross‐linking for bacterial infectious keratitis
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Fungal Keratitis 5. Bacterial Keratitis
Provide patient population that should be included in the study
Treatment regimens for administration of anti‐vascular endothelial growth factor agents for neovascular age‐related macular degeneration
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Age-related Macular Degeneration 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Laser‐assisted in‐situ keratomileusis (LASIK) with a mechanical microkeratome compared to LASIK with a femtosecond laser for LASIK in adults with myopia or myopic astigmatism
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Myopic Astigmatism 5. Young Adult 19-24 years 6. Myopia 7. Aged 65-79 years
Provide patient population that should be included in the study
Intense pulsed light (IPL) therapy for the treatment of meibomian gland dysfunction
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Dry Eyes 5. Young Adult 19-24 years 6. Meibomian Gland Dysfunction 7. Ocular Surface Disease 8. Aged 65-79 years
Provide patient population that should be included in the study
Ab interno trabecular bypass surgery with Schlemm´s canal microstent (Hydrus) for open angle glaucoma
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Ocular Hypertension 5. Borderline open-angle Glaucoma 6. Young Adult 19-24 years 7. Pigmentary Glaucoma 8. Normal tension glaucoma 9. Pseudoexfoliation Glaucoma 10. Aged 65-79 years 11. Open-angle Glaucoma
Provide patient population that should be included in the study
Low vision rehabilitation for better quality of life in visually impaired adults
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Age-related Macular Degeneration 5. Young Adult 19-24 years 6. Visual Impairment 7. Aged 65-79 years 8. Diabetic Retinopathy
Provide patient population that should be included in the study
Toric intraocular lens versus limbal relaxing incisions for corneal astigmatism after phacoemulsification
1. Aged 80 and over 80+ years 2. Middle Aged 45-64 years 3. Phacoemulsification 4. Aged 65-79 years
Provide patient population that should be included in the study
Pars plana vitrectomy combined with scleral buckle versus pars plana vitrectomy for giant retinal tear
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Giant Retinal Tear 4. Adult 19-44 years 5. Child 6-12 years 6. Middle Aged 45-64 years 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Topical cyclosporine A therapy for dry eye syndrome
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Child 6-12 years 4. Sjogren's syndrome 5. Keratoconjunctivitis Sicca 6. Dry Eyes 7. Infant 1 to 23 mo 8. Aqueous Tear Deficiency 9. Aged 65-79 years 10. Adolescent 13-18 years 11. Adult 19-44 years 12. Middle Aged 45-64 years 13. Young Adult 19-24 years 14. Birth to 1 mo 15. Ocular Surface Disease
Provide patient population that should be included in the study
Conventional occlusion versus pharmacologic penalization for amblyopia
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Young Adult 19-24 years 4. Amblyopia 5. Adolescent 13-18 years
Provide patient population that should be included in the study
Intrastromal corneal ring segments for treating keratoconus
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Keratoconus 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Aqueous shunts with mitomycin C versus aqueous shunts alone for glaucoma
1. Aged 80 and over 80+ years 2. Glaucoma 3. Adult 19-44 years 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Ab interno trabecular bypass surgery with iStent for open‐angle glaucoma
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Ocular Hypertension 5. Open angle glaucoma 6. Borderline open-angle Glaucoma 7. Young Adult 19-24 years 8. Pigmentary Glaucoma 9. Normal tension glaucoma 10. Pseudoexfoliation Glaucoma 11. Aged 65-79 years
Provide patient population that should be included in the study
Cyclodestructive procedures for refractory glaucoma
1. Aged 80 and over 80+ years 2. Primary Open Angle Glaucoma 3. Adult 19-44 years 4. Primary Angle-closure Glaucoma 5. Middle Aged 45-64 years 6. Young Adult 19-24 years 7. Pigmentary Glaucoma 8. Neovascular Glaucoma 9. Aged 65-79 years
Provide patient population that should be included in the study
Pars plana vitrectomy versus scleral buckling for repairing simple rhegmatogenous retinal detachments
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Rhegmatogenous Retinal Detachment 6. Aged 65-79 years
Provide patient population that should be included in the study
Endoscopic cyclophotocoagulation (ECP) for open angle glaucoma and primary angle closure
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Primary Angle-closure Glaucoma 4. Middle Aged 45-64 years 5. Ocular Hypertension 6. Borderline open-angle Glaucoma 7. Young Adult 19-24 years 8. Pigmentary Glaucoma 9. Normal tension glaucoma 10. Pseudoexfoliation Glaucoma 11. Aged 65-79 years 12. Open-angle Glaucoma
Provide patient population that should be included in the study
Routine preoperative medical testing for cataract surgery
1. Aged 80 and over 80+ years 2. Extraction Of Cataract 3. Adult 19-44 years 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Anti‐tumour necrosis factor biological therapies for the treatment of uveitic macular oedema (UMO) for non‐infectious uveitis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Uveitis Related Cystoid Macular Edema 6. Middle Aged 45-64 years 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Subconjunctival draining minimally‐invasive glaucoma devices for medically uncontrolled glaucoma
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Ocular Hypertension 5. Borderline open-angle Glaucoma 6. Young Adult 19-24 years 7. Pigmentary Glaucoma 8. Normal tension glaucoma 9. Pseudoexfoliation Glaucoma 10. Aged 65-79 years 11. Open-angle Glaucoma
Provide patient population that should be included in the study
Descemet's membrane endothelial keratoplasty (DMEK) versus Descemet's stripping automated endothelial keratoplasty (DSAEK) for corneal endothelial failure
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Fuchs' Corneal Dystrophy 5. Young Adult 19-24 years 6. Bullous Keratopathy 7. Aged 65-79 years
Provide patient population that should be included in the study
Blue‐light filtering intraocular lenses (IOLs) for protecting macular health
1. Aged 80 and over 80+ years 2. Extraction Of Cataract 3. Adult 19-44 years 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Reading aids for adults with low vision
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Visual Impairment 5. Adolescent 13-18 years
Provide patient population that should be included in the study
Optical correction of refractive error for preventing and treating eye symptoms in computer users
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Computer user 6. Aged 65-79 years 7. Refractive Errors 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Adjustable versus non‐adjustable sutures for strabismus
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Strabismus 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Interventions to increase attendance for diabetic retinopathy screening
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Diabetes Mellitus 6. Aged 65-79 years
Provide patient population that should be included in the study
Anti‐vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity
1. Retinopathy Of Prematurity 2. Birth to 1 mo 3. Preterm Infant
Provide patient population that should be included in the study
Surgical interventions for vertical strabismus in superior oblique palsy
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Strabismus 7. Young Adult 19-24 years 8. Aged 65-79 years 9. Adolescent 13-18 years
Provide patient population that should be included in the study
Interventions to improve access to cataract surgical services and their impact on equity in low‐ and middle‐income countries
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Extraction Of Cataract 4. Adult 19-44 years 5. Child 6-12 years 6. Middle Aged 45-64 years 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Ocriplasmin for symptomatic vitreomacular adhesion
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Vitreomacular Adhesion 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Different‐sized incisions for phacoemulsification in age‐related cataract
1. Aged 80 and over 80+ years 2. Cataract 3. Middle Aged 45-64 years 4. Aged 65-79 years
Provide patient population that should be included in the study
Aqueous shunts for glaucoma
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Glaucoma 4. Adult 19-44 years 5. Child 6-12 years 6. Middle Aged 45-64 years 7. Young Adult 19-24 years 8. Aged 65-79 years 9. Adolescent 13-18 years
Provide patient population that should be included in the study
Probing for congenital nasolacrimal duct obstruction
1. Child, Preschool 2-5 years 2. Infant 1 to 23 mo 3. Congenital Nasolacrimal Duct Obstruction 4. Birth to 1 mo
Provide patient population that should be included in the study
Non‐steroidal anti‐inflammatory drugs versus corticosteroids for controlling inflammation after uncomplicated cataract surgery
1. Aged 80 and over 80+ years 2. Extraction Of Cataract 3. Adult 19-44 years 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Nd:YAG laser vitreolysis versus pars plana vitrectomy for vitreous floaters
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Vitreous Floaters 6. Aged 65-79 years
Provide patient population that should be included in the study
Topical non‐steroidal anti‐inflammatory drugs for analgesia in traumatic corneal abrasions
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Traumatic Corneal Abrasion 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Autologous serum eye drops for dry eye
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Sjogren's syndrome 4. Middle Aged 45-64 years 5. Tear Film Insufficiency 6. Dry Eyes 7. Young Adult 19-24 years 8. Ocular Surface Disease 9. Aged 65-79 years
Provide patient population that should be included in the study
N‐acetylcarnosine (NAC) drops for age‐related cataract
1. Aged 80 and over 80+ years 2. Extraction Of Cataract 3. Middle Aged 45-64 years 4. Aged 65-79 years
Provide patient population that should be included in the study
Endonasal versus external dacryocystorhinostomy for nasolacrimal duct obstruction
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Young Adult 19-24 years 7. Occluded Lacrimal Punctum 8. Aged 65-79 years 9. Adolescent 13-18 years
Provide patient population that should be included in the study
Perioperative medications for preventing temporarily increased intraocular pressure after laser trabeculoplasty
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Infant 1 to 23 mo 5. Young Adult 19-24 years 6. Birth to 1 mo 7. Aged 65-79 years 8. Open-angle Glaucoma
Provide patient population that should be included in the study
Topical medication instillation techniques for glaucoma
1. Aged 80 and over 80+ years 2. Glaucoma 3. Adult 19-44 years 4. Middle Aged 45-64 years 5. Ocular Hypertension 6. Young Adult 19-24 years 7. Aged 65-79 years
Provide patient population that should be included in the study
Surgery for cataracts in people with age‐related macular degeneration
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Age-related Macular Degeneration 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Laser‐assisted subepithelial keratectomy (LASEK) versus laser‐assisted in‐situ keratomileusis (LASIK) for correcting myopia
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Myopia
Provide patient population that should be included in the study
Perioperative antibiotics for prevention of acute endophthalmitis after cataract surgery
1. Aged 80 and over 80+ years 2. Extraction Of Cataract 3. Adult 19-44 years 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Non‐surgical interventions for acute internal hordeolum
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Internal Hordeolum 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Anti‐vascular endothelial growth factor for choroidal neovascularisation in people with pathological myopia
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Choroidal Retinal Neovascularization 5. Degenerative Progressive High Myopia 6. Young Adult 19-24 years 7. Aged 65-79 years
Provide patient population that should be included in the study
Multifocal versus monofocal intraocular lenses after cataract extraction
1. Aged 80 and over 80+ years 2. Extraction Of Cataract 3. Adult 19-44 years 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Fibrin glue versus sutures for conjunctival autografting in primary pterygium surgery
1. Aged 80 and over 80+ years 2. Pterygium 3. Adult 19-44 years 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Oral antivirals for preventing recurrent herpes simplex keratitis in people with corneal grafts
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Corneal Transplant 6. Aged 65-79 years
Provide patient population that should be included in the study
Valacyclovir versus acyclovir for the treatment of herpes zoster ophthalmicus in immunocompetent patients
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Herpes Zoster Ophthalmicus 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Integrated versus non‐integrated orbital implants for treating anophthalmic sockets
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Aged 65-79 years 10. Adolescent 13-18 years 11. Anophthalmos
Provide patient population that should be included in the study
Prophylactic non‐steroidal anti‐inflammatory drugs for the prevention of macular oedema after cataract surgery
1. Aged 80 and over 80+ years 2. Extraction Of Cataract 3. Adult 19-44 years 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Statins for age‐related macular degeneration
1. Aged 80 and over 80+ years 2. Middle Aged 45-64 years 3. Age-related Macular Degeneration 4. Aged 65-79 years
Provide patient population that should be included in the study
Patching for corneal abrasion
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Corneal Abrasion 6. Middle Aged 45-64 years 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Antibiotics versus no treatment for toxoplasma retinochoroiditis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Toxoplasma Retinitis 9. Aged 65-79 years 10. Adolescent 13-18 years
Provide patient population that should be included in the study
Over the counter (OTC) artificial tear drops for dry eye syndrome
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Dry Eyes 4. Young Adult 19-24 years
Provide patient population that should be included in the study
Laser‐assisted subepithelial keratectomy (LASEK) versus photorefractive keratectomy (PRK) for correction of myopia
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Myopia 6. Aged 65-79 years
Provide patient population that should be included in the study
Peripheral iridotomy for pigmentary glaucoma
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Pigment Dispersion Syndrome 8. Young Adult 19-24 years 9. Pigmentary Glaucoma 10. Birth to 1 mo 11. Aged 65-79 years 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Conjunctival autograft for pterygium
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Pterygium 4. Adult 19-44 years 5. Child 6-12 years 6. Middle Aged 45-64 years 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Aflibercept for neovascular age‐related macular degeneration
1. Aged 80 and over 80+ years 2. Middle Aged 45-64 years 3. Age-related Macular Degeneration 4. Aged 65-79 years
Provide patient population that should be included in the study
Doxycycline plus ivermectin versus ivermectin alone for treatment of patients with onchocerciasis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Ocular Onchocerciasis 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Anti‐vascular endothelial growth factor for control of wound healing in glaucoma surgery
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Aged 65-79 years 6. Glaucoma surgery
Provide patient population that should be included in the study
Interventions for dissociated vertical deviation
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Dissociated Vertical Deviation 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Interventions for trachoma trichiasis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Trichiasis 6. Middle Aged 45-64 years 7. Young Adult 19-24 years 8. Aged 65-79 years 9. Adolescent 13-18 years
Provide patient population that should be included in the study
Mitomycin C versus 5‐Fluorouracil for wound healing in glaucoma surgery
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Aged 65-79 years 6. Glaucoma surgery
Provide patient population that should be included in the study
Day care versus in‐patient surgery for age‐related cataract
1. Aged 80 and over 80+ years 2. Extraction Of Cataract 3. Middle Aged 45-64 years 4. Aged 65-79 years
Provide patient population that should be included in the study
Laser treatment of drusen to prevent progression to advanced age‐related macular degeneration
1. Aged 80 and over 80+ years 2. Middle Aged 45-64 years 3. Aged 65-79 years 4. Macular Drusen
Provide patient population that should be included in the study
Intravitreal steroids versus observation for macular edema secondary to central retinal vein occlusion
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Young Adult 19-24 years 7. Aged 65-79 years 8. Central Retinal Vein Occlusion With Macular Edema 9. Adolescent 13-18 years
Provide patient population that should be included in the study
Sub‐Tenon's anaesthesia versus topical anaesthesia for cataract surgery
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Cataract Surgery 6. Aged 65-79 years
Provide patient population that should be included in the study
Immunosuppressants for the prophylaxis of corneal graft rejection after penetrating keratoplasty
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Aged 65-79 years 6. Penetrating Keratoplasty
Provide patient population that should be included in the study
Corticosteroids for treating optic neuritis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Young Adult 19-24 years 7. Optic Neuritis 8. Birth to 1 mo 9. Aged 65-79 years 10. Adolescent 13-18 years
Provide patient population that should be included in the study
Interventions for idiopathic intracranial hypertension
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Child 6-12 years 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Benign Intracranial Hypertension 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Combined surgery versus cataract surgery alone for eyes with cataract and glaucoma
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Cataract 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Pigmentary Glaucoma 7. Pseudoexfoliation Glaucoma 8. Aged 65-79 years 9. Open-angle Glaucoma
Provide patient population that should be included in the study
Assistive technology for children and young people with low vision
1. Child 6-12 years 2. Visual Impairment 3. Adolescent 13-18 years
Provide patient population that should be included in the study
Macular grid laser photocoagulation for branch retinal vein occlusion
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Branch Retinal Vein Occlusion With Macular Edema 6. Aged 65-79 years
Provide patient population that should be included in the study
Medical interventions for fungal keratitis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Fungal Keratitis 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Surgery for nonarteritic anterior ischemic optic neuropathy
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Non-arteritic Ischemic Optic Neuropathy 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Optical reading aids for children and young people with low vision
1. Child 6-12 years 2. Visual Impairment 3. Adolescent 13-18 years
Provide patient population that should be included in the study
Medical interventions for acanthamoeba keratitis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Acanthamoeba keratitis 6. Middle Aged 45-64 years 7. Young Adult 19-24 years 8. Aged 65-79 years 9. Adolescent 13-18 years
Provide patient population that should be included in the study
Face washing promotion for preventing active trachoma
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Young Adult 19-24 years 7. Trachoma 8. Aged 65-79 years 9. Adolescent 13-18 years
Provide patient population that should be included in the study
Antiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Dendritic Keratitis 7. Young Adult 19-24 years 8. Punctate Epithelial Keratitis 9. Aged 65-79 years 10. Adolescent 13-18 years 11. Herpes Simplex Virus Epithelial Keratitis
Provide patient population that should be included in the study
Interventions for asymptomatic retinal breaks and lattice degeneration for preventing retinal detachment
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Retinal Detachment 5. Young Adult 19-24 years 6. Asymptomatic 7. Retinal Lattice Degeneration 8. Multiple Retinal Breaks 9. Aged 65-79 years
Provide patient population that should be included in the study
Excimer laser refractive surgery versus phakic intraocular lenses for the correction of moderate to high myopia
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Myopia
Provide patient population that should be included in the study
D‐Penicillamine for preventing retinopathy of prematurity in preterm infants
1. Birth to 1 mo 2. Preterm Infant
Provide patient population that should be included in the study
Vitamin D for the treatment of inflammatory bowel disease
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Inflammatory Bowel Disease 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Fibrin‐based haemostatic agents for reducing blood loss in adult liver resection
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Liver Excision 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Prostaglandins for adult liver transplanted recipients
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Liver transplant 6. Aged 65-79 years
Provide patient population that should be included in the study
Expanded polytetrafluoroethylene (ePTFE)‐covered stents versus bare stents for transjugular intrahepatic portosystemic shunt in people with liver cirrhosis
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Liver cirrhosis 6. Aged 65-79 years
Provide patient population that should be included in the study
Rifaximin for prevention and treatment of hepatic encephalopathy in people with cirrhosis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Hepatic Encephalopathy 9. Birth to 1 mo 10. Liver cirrhosis 11. Aged 65-79 years 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Fibrin sealants for the prevention of postoperative pancreatic fistula following pancreatic surgery
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Pancreatic disorder 4. Adult 19-44 years 5. Child 6-12 years 6. Middle Aged 45-64 years 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Granulocyte colony‐stimulating factor with or without stem or progenitor cell or growth factors infusion for people with compensated or decompensated advanced chronic liver disease
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Chronic Liver Disease 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Exercise interventions for adults after liver transplantation
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Liver transplant 6. Aged 65-79 years
Provide patient population that should be included in the study
Remote care through telehealth for people with inflammatory bowel disease
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Child 6-12 years 4. Infant 1 to 23 mo 5. Aged 65-79 years 6. Adolescent 13-18 years 7. Adult 19-44 years 8. Crohn's Disease 9. Middle Aged 45-64 years 10. Ulcerative Colitis 11. Young Adult 19-24 years 12. Birth to 1 mo 13. Inflammatory Bowel Disease
Provide patient population that should be included in the study
Patient education interventions for the management of inflammatory bowel disease
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Inflammatory Bowel Disease 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Erythromycin prior to endoscopy for acute upper gastrointestinal haemorrhage
1. Upper Gastrointestinal Hemorrhage
Provide patient population that should be included in the study
Interventions to improve sanitation for preventing diarrhoea
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Aged 65-79 years 10. Adolescent 13-18 years
Provide patient population that should be included in the study
Fundoplication in laparoscopic Heller's cardiomyotomy for achalasia
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Achalasia 6. Aged 65-79 years
Provide patient population that should be included in the study
Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Typhoid Fever 7. Young Adult 19-24 years 8. Aged 65-79 years 9. Paratyphoid Fever 10. Adolescent 13-18 years
Provide patient population that should be included in the study
Electromagnetic‐guided versus endoscopic‐guided postpyloric placement of nasoenteral feeding tubes
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Aged 65-79 years 6. Tube Feeding
Provide patient population that should be included in the study
Certolizumab pegol for maintenance of medically induced remission in Crohn’s disease
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Crohn's Disease 6. Middle Aged 45-64 years 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Physical activity for treatment of irritable bowel syndrome
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Irritable bowel syndrome 6. Aged 65-79 years
Provide patient population that should be included in the study
Antibiotics for uncomplicated diverticulitis
1. Diverticulitis
Provide patient population that should be included in the study
Stem cell transplantation for induction of remission in medically refractory Crohn’s disease
1. Crohn's Disease
Provide patient population that should be included in the study
Tacrolimus (FK506) for induction of remission in corticosteroid‐refractory ulcerative colitis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Ulcerative Colitis 7. Young Adult 19-24 years 8. Aged 65-79 years 9. Adolescent 13-18 years
Provide patient population that should be included in the study
Guidewire‐assisted cannulation of the common bile duct for the prevention of post‐endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Pancreatitis 6. Aged 65-79 years
Provide patient population that should be included in the study
Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding
1. Hospitalization 2. Gastrointestinal Bleeding
Provide patient population that should be included in the study
Intraperitoneal local anaesthetic instillation versus no intraperitoneal local anaesthetic instillation for laparoscopic cholecystectomy
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Aged 65-79 years 10. Laparoscopic Cholecystostomy 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Mesh fixation techniques in primary ventral or incisional hernia repair
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Hernia Of Anterior Abdominal Wall 5. Young Adult 19-24 years 6. Ventral Incisional Hernia 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Primary prevention of variceal bleeding in people with oesophageal varices due to liver cirrhosis: a network meta‐analysis
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Liver cirrhosis 6. Aged 65-79 years 7. Esophageal Varices
Provide patient population that should be included in the study
Secondary prevention of variceal bleeding in adults with previous oesophageal variceal bleeding due to decompensated liver cirrhosis: a network meta‐analysis
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Decompensated Cirrhosis 6. Aged 65-79 years 7. Esophageal Varices
Provide patient population that should be included in the study
Risk of postoperative infectious complications from medical therapies in inflammatory bowel disease
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Crohn's Disease 4. Middle Aged 45-64 years 5. Indeterminate Colitis 6. Ulcerative Colitis 7. Surgery 8. Young Adult 19-24 years 9. Aged 65-79 years
Provide patient population that should be included in the study
Portosystemic shunts versus endoscopic intervention with or without medical treatment for prevention of rebleeding in people with cirrhosis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Liver cirrhosis 10. Aged 65-79 years 11. Adolescent 13-18 years 12. Esophageal Varices
Provide patient population that should be included in the study
Interventions for preventing postpartum constipation
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Postpartum 4. Young Adult 19-24 years 5. Constipation 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Adalimumab for maintenance of remission in Crohn's disease
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Crohn's Disease In Remission 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Aged 65-79 years 10. Adolescent 13-18 years
Provide patient population that should be included in the study
Antibiotic prophylaxis for prevention of postoperative wound infection in adults undergoing open elective inguinal or femoral hernia repair
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Open Repair Of Inguinal Hernia 6. Open Repair Of Femoral Hernia 7. Aged 65-79 years
Provide patient population that should be included in the study
Nasogastric versus nasojejunal tube feeding for severe acute pancreatitis
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Acute pancreatitis 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Anti‐IL‐12/23p40 antibodies for maintenance of remission in Crohn's disease
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Crohn's Disease In Remission 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Adalimumab for induction of remission in Crohn's disease
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Crohn's Disease 6. Middle Aged 45-64 years 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Band ligation versus beta‐blockers for primary prophylaxis of oesophageal variceal bleeding in children with chronic liver disease or portal vein thrombosis
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Chronic Liver Disease 4. Infant 1 to 23 mo 5. Birth to 1 mo 6. Portal Vein Thrombosis 7. Adolescent 13-18 years 8. Esophageal Varices
Provide patient population that should be included in the study
Certolizumab pegol for induction of remission in Crohn's disease
1. Adult 19-44 years 2. Crohn's Disease 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Adolescent 13-18 years
Provide patient population that should be included in the study
Plasma expanders for people with cirrhosis and large ascites treated with abdominal paracentesis
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Ascites 5. Liver cirrhosis
Provide patient population that should be included in the study
Lateral pararectal versus transrectal stoma placement for prevention of parastomal herniation
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Enterostomy 8. Abdominal Wall Procedure 9. Young Adult 19-24 years 10. Birth to 1 mo 11. Aged 65-79 years 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Adjuvant therapy with antidepressants for the management of inflammatory bowel disease
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Inflammatory Bowel Disease 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Glucocorticosteroids for people with alcoholic hepatitis
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Alcoholic Hepatitis 6. Aged 65-79 years
Provide patient population that should be included in the study
N‐acetylcysteine as an adjuvant therapy for Helicobacter pylori eradication
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Helicobacter Pylori Infection 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Antibiotics for induction and maintenance of remission in Crohn's disease
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Crohn's Disease 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Acetyl‐L‐carnitine for patients with hepatic encephalopathy
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Hepatic Encephalopathy 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Cannabis for the treatment of ulcerative colitis
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Ulcerative Colitis 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Surgical portosystemic shunts versus transjugular intrahepatic portosystemic shunt for variceal haemorrhage in people with cirrhosis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Child 6-12 years 4. Portal Hypertension 5. Infant 1 to 23 mo 6. Aged 65-79 years 7. Adolescent 13-18 years 8. Adult 19-44 years 9. Middle Aged 45-64 years 10. Young Adult 19-24 years 11. Birth to 1 mo 12. Liver cirrhosis 13. Oesophageal Varices With Bleeding, Associated With Another Disorder
Provide patient population that should be included in the study
Swallowing therapy for dysphagia in acute and subacute stroke
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Hemorrhagic Cerebral Infarction 5. Young Adult 19-24 years 6. Ischemic Stroke 7. Dysphagia 8. Aged 65-79 years 9. Adolescent 13-18 years
Provide patient population that should be included in the study
Carvedilol versus traditional, non‐selective beta‐blockers for adults with cirrhosis and gastroesophageal varices
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Liver cirrhosis 6. Aged 65-79 years 7. Esophageal Varices Associated With Another Disorder
Provide patient population that should be included in the study
Prokinetics for functional dyspepsia
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Nonulcer Dyspepsia 6. Aged 65-79 years
Provide patient population that should be included in the study
Modifying the consistency of food and fluids for swallowing difficulties in dementia
1. Difficulty Swallowing 2. Dementia
Provide patient population that should be included in the study
Mesh versus non‐mesh for inguinal and femoral hernia repair
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Inguinal Hernia 5. Young Adult 19-24 years 6. Femoral Hernia 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Epidural analgesia versus patient‐controlled intravenous analgesia for pain following intra‐abdominal surgery in adults
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Abdominal Wall Procedure 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years